**Core Concept**
Glipizide is a second-generation sulfonylurea, which acts on the pancreas to increase insulin release. This involves the closure of potassium channels in the beta cells, leading to an influx of calcium ions, and ultimately the release of insulin.

**Why the Correct Answer is Right**
Glipizide binds to the sulfonylurea receptor (SUR1), which is a subunit of the ATP-sensitive potassium channel (K_ATP) in pancreatic beta cells. This binding causes the closure of the potassium channels, depolarization of the cell membrane, and an influx of calcium ions. The increase in intracellular calcium triggers the exocytosis of insulin-containing vesicles, leading to an increase in insulin secretion. This action is specific to the pancreatic beta cells and does not affect other cells in the body.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not specify the mechanism of action of glipizide. While it is true that sulfonylureas increase insulin release, this option does not provide any further information about the specific action of glipizide.

**Option B:** This option is incorrect as it suggests that glipizide acts by inhibiting the release of glucagon. While glucagon and insulin are both hormones involved in glucose metabolism, glipizide's primary action is to increase insulin release, not inhibit glucagon release.

**Option C:** This option is incorrect as it suggests that glipizide acts by stimulating the release of insulin from the liver. Glipizide's action is specific to the pancreatic beta cells, not the liver.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that sulfonylureas like glipizide can cause hypoglycemia as a side effect, especially when used in combination with other glucose-lowering medications or in patients with renal impairment.

**Correct Answer: C. Glipizide binds to the sulfonylurea receptor (SUR1), causing closure of potassium channels and an increase in insulin secretion.**